Search

As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.

… Tuesday, December 5, 2017 This past year, Memorial Sloan Kettering researchers made important advances in basic and translational science that furthered our understanding of cancer and of how best to treat it. Here, we describe some of the year’s highlights. First CAR T Cell Therapies FDA Approved By

Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK's drug development resources and a pathway for future collaboration via the Accelerator.

… Wednesday, April 30, 2025 MSK recently announced the launch of a new cohort program in the MSK Therapeutics Accelerator . Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK’s drug development resources and a pathway

Research points to the role of a protein called MYB, which has long been known to play a role in cancer.

… Friday, February 5, 2021 Summary Research shows how a protein called MYB can be targeted, suggesting a new approach for drugs that could treat a range of cancers, especially myeloid leukemias in both children and adults. Disruption in the way genes turn on and off can cause tumors to grow and proliferate

Research by a team at Memorial Sloan Kettering Cancer Center has found important new insights into colorectal cancer in Nigeria that have significant implications for treating the disease in West Africa. This research also expands awareness of how different population groups may require different approaches in the diagnosis and treatment of cancer.

… Wednesday, November 24, 2021 Colorectal cancer is common — and deadly — around the world.   But too often, major population groups are not represented in colorectal cancer research, which focuses mainly on patients in America and Western Europe.   A team of researchers from Memorial Sloan Kettering Cancer

The Patient and Family Advisory Council for Quality (PFACQ) marks five years of ensuring the patient and family perspective is included in everything MSK does.

… Wednesday, January 1, 2020 In 2014, Kate Niehaus, a former patient active in volunteer work for Memorial Sloan Kettering, was approached by Kent Sepkowitz, an infectious disease specialist and Deputy Physician-in-Chief for Quality and Safety, with a proposal to make MSK’s outstanding cancer care even

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.

… Wednesday, October 29, 2025 On October 24, 2025, the U.S. Food and Drug Administration (FDA)  approved revumenib (Revuforj ® ) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called an NPM1 mutation. In November 2024,

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute finds tumor-associated macrophages that express a specific transcription factor might be targeted to improve immunotherapy; examines how different mutational processes impact individual cell genomes in cancer; sheds new light on cell senescence in cancer; and offers new models to aid the search for new treatments for mesothelioma.

… Wednesday, November 23, 2022 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — MSK’s experimental research arm — finds tumor-associated macrophages that express a specific transcription factor might be targeted to improve immunotherapy; examines how different

The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research.

… Thursday, December 6, 2012 Summary The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research. The Geoffrey Beene Foundation is featuring six Memorial Sloan Kettering researchers in its current

Discover how Memorial Sloan Kettering is teaming up with local hospitals to promote healthy eating in diverse communities.

… Monday, October 4, 2021 Update: On June 16, 2022 Dr. Gany and her team published the results of a groundbreaking study, the first of its kind, in the  Journal of Clinical Oncology .  After six months of study enrollment, researchers found that patients who received a debit card for groceries and had

Descubre cómo Memorial Sloan Kettering se está uniendo a hospitales locales para promover la alimentación saludable en la comunidad latina.

… Monday, October 4, 2021 Se sabe que una dieta saludable ayuda a prevenir el cáncer. Pero una dieta saludable también es fundamental después de diagnosticar a los pacientes. Los tratamientos contra el cáncer pueden quitar el apetito a los pacientes. Sin embargo, deben alimentarse bien para estar lo suficientemente